Disease Landscape and Forecast Insights

Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

The wet age-related macular degeneration (AMD) market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Novartis’s…

Immune thrombocytopenia purpura (ITP) is an autoimmune form of acquired thrombocytopenia that leads to a decrease in platelet production and an increased risk of bleeding. Current therapies for ITP…

Tumor necrosis factor (TNF)-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira, biosimilars of both drugs, where available) are the mainstay of biological treatment for moderate to…

Immune thrombocytopenia purpura (ITP) is an autoimmune form of acquired thrombocytopenia that leads to a decrease in platelet production and an increased risk of bleeding. Current therapies for ITP…

Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the…

The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier…

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. The well-established TNF-α inhibitors (e…

The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for moderate to severe…

The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio…

The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second…

A series of launches are expected to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market over the next 10 years and challenge the dominance of the TNF inhibitors; the impact…